• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Alzheimer's disease treatment landscape: current therapies and emerging mechanism-targeted approaches.

作者信息

Yang Eleen, Abd-Elrahman Khaled S

机构信息

Department of Anesthesiology, Pharmacology and Therapeutics, and Djavad Mowafaghian Center for Brain Health, University of British Columbia, Vancouver, BC, Canada (Yang E, Abd-Elrahman KS).

Department of Medical Sciences, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates (Abd-Elrahman KS).

出版信息

Neural Regen Res. 2025 Dec 1;20(12):3531-3532. doi: 10.4103/NRR.NRR-D-24-00934. Epub 2024 Nov 13.

DOI:10.4103/NRR.NRR-D-24-00934
PMID:39589513
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11974664/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8742/11974664/efba010bc3f2/NRR-20-3531-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8742/11974664/efba010bc3f2/NRR-20-3531-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8742/11974664/efba010bc3f2/NRR-20-3531-g001.jpg

相似文献

1
Alzheimer's disease treatment landscape: current therapies and emerging mechanism-targeted approaches.阿尔茨海默病的治疗现状：当前疗法及新兴的机制靶向治疗方法
Neural Regen Res. 2025 Dec 1;20(12):3531-3532. doi: 10.4103/NRR.NRR-D-24-00934. Epub 2024 Nov 13.
2
Navigating the Alzheimer's Treatment Landscape: Unraveling Amyloid-beta Complexities and Pioneering Precision Medicine Approaches.探索阿尔茨海默病治疗领域：解析淀粉样蛋白-β的复杂性与开拓精准医学方法。
Curr Top Med Chem. 2024;24(19):1665-1682. doi: 10.2174/0115680266295495240415114919.
3
Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers.解决美国商业支付者新阿尔茨海默病治疗替代支付模式面临的挑战。
Pharmacoeconomics. 2022 Jul;40(7):647-652. doi: 10.1007/s40273-022-01150-w. Epub 2022 May 13.
4
Alzheimer's disease drug development in an evolving therapeutic landscape.不断演变的治疗格局下的阿尔茨海默病药物研发
Alzheimers Dement (N Y). 2024 Nov 30;10(4):e70015. doi: 10.1002/trc2.70015. eCollection 2024 Oct-Dec.
5
Recent Trends in the Management of Alzheimer's Disease: Current Therapeutic Options and Drug Repurposing Approaches.阿尔茨海默病管理的最新趋势：当前的治疗选择和药物再利用方法。
Curr Neuropharmacol. 2020;18(9):868-882. doi: 10.2174/1570159X18666200128121920.
6
Advances in therapies and scope for personalized medicine in Alzheimer's disease.阿尔茨海默病治疗进展与个性化医疗前景
Per Med. 2016 Mar;13(2):189-199. doi: 10.2217/pme.15.49. Epub 2016 Feb 8.
7
Alzheimer's disease: from molecular pathogenesis to innovative therapies.阿尔茨海默病：从分子发病机制到创新疗法。
Expert Rev Neurother. 2003 Sep;3(5):619-30. doi: 10.1586/14737175.3.5.619.
8
Novel Therapeutic Strategies in Alzheimer's Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond.阿尔茨海默病的新型治疗策略：抗淀粉样蛋白疗法及其他疗法的陷阱与挑战
J Clin Med. 2024 May 25;13(11):3098. doi: 10.3390/jcm13113098.
9
Emerging paradigms in Alzheimer's therapy.阿尔茨海默病治疗的新范例。
Eur J Pharmacol. 2024 Oct 15;981:176872. doi: 10.1016/j.ejphar.2024.176872. Epub 2024 Aug 6.
10
Neuromodulation in the Treatment of Alzheimer's Disease: Current and Emerging Approaches.神经调节治疗阿尔茨海默病：当前和新兴方法。
J Alzheimers Dis. 2020;78(4):1299-1313. doi: 10.3233/JAD-200913.

引用本文的文献

1
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition.针对tau片段的免疫疗法可减轻阿尔茨海默病病理，改善突触功能和认知。
Mol Neurodegener. 2025 May 27;20(1):60. doi: 10.1186/s13024-025-00854-9.

本文引用的文献

1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
2
Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future.阿尔茨海默病的淀粉样β为基础的治疗：挑战、成功与未来。
Signal Transduct Target Ther. 2023 Jun 30;8(1):248. doi: 10.1038/s41392-023-01484-7.
3
Tacrine-Based Hybrids: Past, Present, and Future.他克林类杂合体：过去、现在和未来。
Int J Mol Sci. 2023 Jan 15;24(2):1717. doi: 10.3390/ijms24021717.
4
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
5
Alzheimer's disease drug development pipeline: 2022.2022年阿尔茨海默病药物研发进展
Alzheimers Dement (N Y). 2022 May 4;8(1):e12295. doi: 10.1002/trc2.12295. eCollection 2022.
6
γ-Secretase in Alzheimer's disease.γ-分泌酶在阿尔茨海默病中的作用。
Exp Mol Med. 2022 Apr;54(4):433-446. doi: 10.1038/s12276-022-00754-8. Epub 2022 Apr 8.
7
A positive allosteric modulator for the muscarinic receptor (M1 mAChR) improves pathology and cognitive deficits in female APPswe/PSEN1ΔE9 mice.一种毒蕈碱型乙酰胆碱受体（M1 mAChR）的正变构调节剂可改善 APPswe/PSEN1ΔE9 雌性小鼠的病理和认知缺陷。
Br J Pharmacol. 2022 Apr;179(8):1769-1783. doi: 10.1111/bph.15750. Epub 2022 Feb 3.
8
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.在两项评估早期阿尔茨海默病患者使用 aducanumab 的 3 期研究中，淀粉样蛋白相关成像异常。
JAMA Neurol. 2022 Jan 1;79(1):13-21. doi: 10.1001/jamaneurol.2021.4161.
9
APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function.载脂蛋白 E 免疫疗法可减少脑淀粉样血管病和淀粉样斑块，同时改善脑血管功能。
Sci Transl Med. 2021 Feb 17;13(581). doi: 10.1126/scitranslmed.abd7522.
10
Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.水合甲基硫氨酸对轻度至中度阿尔茨海默病认知下降和脑萎缩的浓度依赖性作用。
J Alzheimers Dis. 2019;72(3):931-946. doi: 10.3233/JAD-190772.